Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
Many international patients who look into regenerative medicine in Japan have a doctor back home who knows their history well. That doctor may manage a long-term condition, prescribe medicines, or coordinate imaging and tests. When you begin to consider adipose-derived stem cell therapy in Osaka, it is natural to wonder how that relationship fits in. This article explains why involving your home doctor can help, and what to prepare before you speak with Grand Green Osaka Umekita Clinic.
The short answer: treat it as a shared decision
Adipose-derived stem cell therapy is a regenerative medicine option in which mesenchymal stem cells taken from your own fat tissue are cultured and then returned to your body by IV infusion. It is not a replacement for the care you already receive, and it does not suit every person. A careful decision usually involves more than one clinician: the doctor who knows your long-term history and the physician who would provide this treatment after an in-person consultation.
Bringing your home doctor into the conversation does not mean asking for permission. It means giving yourself a second informed perspective, so that you can weigh the information with a full picture of your health.
Why your home doctor’s view matters
Your home doctor knows things that a single consultation abroad may not capture quickly: how your condition has changed over the years, which treatments you have already tried, how you have responded to medicines, and whether you have other conditions that affect planning. Research on mesenchymal stem cells is active worldwide, including studies on joint conditions such as osteoarthritis, but results vary between studies and the evidence is still developing. A physician who follows your case can help you place any single treatment in that wider context.
Your home doctor can also help you think about timing. For example, some people are in the middle of another treatment plan, are waiting for a scheduled procedure, or take medicines that a treating physician will want to know about. These are questions to raise early rather than on the day of travel.
Records and information worth gathering first
A consultation is more useful when the physician can see your background clearly. Before you contact the clinic, consider asking your home doctor’s office for the following, in English if possible:
- A short summary of your diagnosis and the main treatments you have received so far
- A current list of medicines, supplements and known allergies
- Recent blood test results and any relevant imaging reports
- Notes on past surgeries, infections or reactions to anesthesia
- The name and contact details of the doctor who should receive updates afterward
If your documents are not in English, mention this when you first get in touch so that the clinic can explain what it can and cannot review. Grand Green Osaka Umekita Clinic provides an information page for international patients, which is a helpful place to start when you are unsure how to begin.
Understanding the Japanese framework before you speak
Your home doctor may be unfamiliar with how regenerative medicine is organized in Japan, so it helps to explain the basics. In Japan, treatments of this kind are provided under the Act on the Safety of Regenerative Medicine, which requires clinics to follow a regenerative medicine provision plan. This treatment is offered as a self-pay (non-insured) service, which means national health insurance does not cover it. Costs, risks, possible side effects and whether the treatment is appropriate for you must all be confirmed through a consultation with a physician.
It is also reasonable to tell your home doctor that treatments offered under this framework are not the same as approved drugs with a long record of large trials. Saying so plainly lets them give you candid advice and helps you ask better questions.
Questions to bring to both doctors
Writing your questions down makes both conversations more productive. Some people find it useful to ask the same core questions of each physician and compare the answers.
- Is there anything in my medical history that could make this treatment unsuitable or call for extra caution?
- How does this option relate to the standard care I already receive, and should any of that continue unchanged?
- What is known, and what is still uncertain, about the evidence for my specific condition?
- What risks and side effects should I understand, including those related to fat collection and infusion?
- What would a realistic follow-up plan look like once I am back home?
- Who should I contact if I have a concern after I return?
Treat any answer that sounds like a promise with caution. Responsible physicians describe what is reported in studies and what remains uncertain, and they explain that individual responses differ.
Planning follow-up after you return home
Treatment is only one part of the journey. After you go home, you may want your own doctor to keep monitoring your condition, review new symptoms and continue any ongoing care. It helps to agree before you travel on how information will move between the two sides. Ask the clinic what records it can provide after treatment, such as a summary of the procedure, and ask your home doctor whether they are willing to receive and review that summary.
Some home doctors will be supportive, some neutral and some skeptical. All three reactions are useful information. A cautious opinion is not a reason to dismiss the idea, and an enthusiastic one is not a reason to skip your own questions. The goal is to make an informed choice that you understand.
Taking the next step in Osaka
If you decide to learn more, you can arrange a consultation with Grand Green Osaka Umekita Clinic, located in Umeda, Osaka. During the consultation, the physician can review your history, explain how the process works from fat collection to cell culture and infusion, and discuss fees, risks and whether the treatment is appropriate for you. You are free to ask questions, take time to think, and decide not to proceed.
In summary, bringing your home doctor into the decision gives you better information, clearer expectations and a smoother plan for follow-up. Gather your records, explain the Japanese framework, write down your questions, and use both physicians’ views to decide what is right for you.
- Gather your recordsSummary, medicines, test results
- Involve both doctorsCompare their views
- Keep standard care in viewNot a replacement
- Plan follow-up at homeAgree how records are shared
This figure is a conceptual summary of the article content
References
- PubMed: Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. (2023)
- PubMed: Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. (2019)
- PubMed: Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. (2019)
- PubMed: Cartilage Regeneration Potential in Early Osteoarthritis of the Knee: A Prospective, Randomized, Open, and Blinded Endpoint Study Comparing Adipose-Derived Mesenchymal Stem Cell (ADSC) Therapy Versus Hyaluronic Acid. (2025)
- PubMed: Safety and efficacy of adipose-derived mesenchymal stem cells for knee osteoarthritis: A systematic review and m-analysis. (2022)
- PMC: What is the optimal dose of adipose-derived mesenchymal stem cells treatment for knee osteoarthritis? A conventional and network meta-analysis of randomized controlled trials. (2023)
- PMC: Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy – a review. (2016)
- PMC: Efficacy based on dose-response and safety of bone marrow-derived mesenchymal stem cells for the treatment of osteoarthritis: a systematic review and meta-analysis. (2025)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.